DNA vaccine against amyloid-beta and tau

Abstract

An object of the present invention is to provide a vaccine that can simultaneously reduce Aβ deposition and tau deposition in the brain by means of a single molecule. The present invention provides a recombinant vector comprising DNA encoding amyloid-β, DNA encoding an immunoglobulin Fc sequence, and DNA encoding tau.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a Continuation of copending application Ser. No. 15 / 578,123, filed on Nov. 29, 2017, which is a 35 U.S.C. 371 National Stage of PCT International Application No. PCT / JP2016 / 081038 on Oct. 20, 2016, which claims the benefit under 35 U.S.C. § 119(a) to Patent Application No. 2015-207888, filed in Japan on Oct. 22, 2015, all of which are hereby expressly incorporated by reference into the present application.TECHNICAL FIELD[0002]The present invention relates to DNA vaccines against amyloid-β and tau.BACKGROUND ART[0003]Alzheimer's disease is a disease in which moderate to severe cerebral atrophy is grossly visible in the frontal association cortex, temporal lobe, and hippocampal region, and is characterized by three major microscopic findings, i.e., senile plaques (amyloid-β (Aβ) deposition), neurofibrillary tangles (hyperphosphorylated tau deposition), and neuronal loss.[0004]There are many reports that amyloid accumulat...

AI Technical Summary

Benefits of technology

The approach effectively induces antibodies against both Aβ and tau, leading to a significant reduction in brain Aβ and tau deposition, particularly phosphorylated tau, which is strongly neurotoxic, thus providing a promising treatment or prevention for Alzheimer's disease.

Problems solved by technology

From pathological examination, however, it has been reported that although anti-immunotherapy effectively reduces Aβ deposition, its effect of reducing tau deposition is extremely weak (Non Patent Literature 1: Boche, D. et al., Acta Neuropathol 120, 13-20).

At present, DNA vaccines against Aβ are known (Patent Literature 1: WO 2010 / 110408); however, no DNA vaccine is known that can reduce Aβ deposition and tau deposition simultaneously by means of a single molecule.

Images